Fig. 2.

Clinical analysis of amyotrophic lateral sclerosis (ALS) patients during the follow-up period. (A) Regression analysis of ALS Functional Rating Scale–Revised (ALSFRS-R) score changes in 15 patients treated with autologous bone marrow-derived mesenchymal stem cells (BM-MSCs). The y-axis shows the ALSFRS-R scores, and the x-axis shows the clinical visits with comparing time courses in months. There was a significant reduction ALSFRS-R 6 months after the treatment. (B) Time courses of ALSFRS-R scores in the individual patients. (C) Regression analysis of forced vital capacity (FVC) changes in 15 patients (y-axis indicates the percentage of FVC and the x-axis indicates clinical visits with comparing time courses in months). There was a significant reduction in FVC 6 months after the application of BM-MSCs. D) FVC scores of the individual patient during the follow-up period.